Massimo Boriero joined Orphalan in 2021, but he played an instrumental role building GMP-Orphan commercial organization, back in 2018.
He brings more than 25 years of international pharmaceutical industry experience in commercialization, market access, strategic and business development.
Most recently he served as Vice-President & General Manager Southern Europe, France & BeNeLux at Akcea Therapeutics, where he led the founding and build-up of the complete business and organization.
Prior to Akcea, he managed the establishment and commercial set-up of the European Business at Spark Therapeutics, later acquired by Roche and, prior to that, he served as President, EMEA, at Aegerion Pharmaceuticals.
In a period of 17 years before this he had been working in several management positions at national and international level for Genzyme Therapeutics.
Massimo is a physician by education, trained in Turin and at Harvard Business School.